radionuclide conjugates 225ac-j591 and 177lu-psma-i&t for mcrpc
Published 2 years ago • 572 plays • Length 3:30Download video MP4
Download video MP3
Similar videos
-
3:07
psma-trt, 225ac-j591 and 177lu-psma i&t in mcrpc
-
7:14
psma-targeted alpha emitter 225ac-j591 for mcrpc
-
0:40
psma pet findings in 225ac-j591-treated patients with mcrpc
-
5:47
phase i/ii dose-escalation study of 225ac-j591 in progressive mcrpc
-
6:40
a single fractionated cycle of 225ac-j591 shows preliminary efficacy on mcrpc patients
-
7:52
does high psa levels = prostate cancer? | dr steven tucker
-
15:35
lu-psma radioligand therapy
-
8:49
limitations of lutetium-177-psma & addressing treatment challenges
-
5:27
177lu-psma-617 radionuclide therapy in mcrpc
-
1:38
177lu-psma i&t for patients with psma-positive mcrpc
-
1:00
is there are role for 177lu-psma-617 in earlier lines of treatment for mcrpc?
-
2:37
therap: cabazitaxel versus 177lu-psma-617 for mcrpc
-
4:48
vision: lu-177-psma-617 in mcrpc
-
1:49
dr. tagawa on preliminary data with 225ac-j591 in mcrpc
-
3:03
vision: tolerability of 177lu-psma-617 by treatment exposure in patients with mcrpc
-
3:30
how to administer the investigational radiopharmaceutical 177lu-psma-i&t
-
2:04
phase i/ii trial of 177lu−j591 and 177lu−psma−617 in mcrcp
-
2:24
eclipse - a randomized phase 3 trial for 177-lu-psma-i&t in patients with mcrpc
-
1:08
psma imaging pre- and post-177lu-psma-617 treatment in mcrpc
-
5:30
fractionated dose 177lu-psma-617 in patients with mcrpc
-
6:45
177lu-psma-617 for prostate cancer: therap, vision, upfrontpsma and lutectomy
-
1:35
vision: safety analysis of 177lu-psma-617 in mcrpc